News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Biogen Idec, Inc. (Massachusetts) Initiates Phase III Clinical Program Of Oral Compound BG-12 For Multiple Sclerosis
January 9, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) announced today that it has initiated the Phase III clinical program of BG-12, an oral fumarate in development for relapsing-remitting multiple sclerosis (MS).
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Biogen
MORE ON THIS TOPIC
Insights
The untapped potential of drug repurposing
November 19, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Alzheimer’s disease
CTAD 2026: BMS’ Cobenfy eases Alzheimer’s psychosis as expected but safety events raise questions
November 18, 2026
·
4 min read
·
Annalee Armstrong
Alzheimer’s disease
CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s
November 18, 2026
·
6 min read
·
Heather McKenzie
Drug Development
Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns
November 18, 2026
·
2 min read
·
Gabrielle Masson